"Colombia Pharmaceuticals & Healthcare Report Q3 2016" Published

Colombia's deteriorating regulatory regime will continue to limit the country's attractiveness to multinational pharmaceutical companies in the coming years. Despite the country's growing rates of medicine consumption, the increasing compulsory license risks and patent regulation burdens as well as substandard pricing controls will remain critical threats to pharmaceutical investment in the country over the long term .

Headline Expenditure Projections

Pharmaceuticals: COP9,101bn (USD3.31bn) in 2015 to COP9,581bn (USD3.10bn) in 2016; +5.3% in local currency and -6.6% in US dollars.
Healthcare: COP59,425bn (USD21.6bn) in 2015 to COP64,692bn (USD20.9bn) in 2016; +8.9% in local currency and -3.4% in US dollars.

Risk/Reward Index

Full Report Details at
- http://www.fastmr.com/prod/1188089_colombia_pharmaceuticals.aspx?afid=301

In our Q316 regional Risk/Reward Index, Colombia is ranked eighth oout of 19 markets surveyed in the Americas region, unchanged from the previous quarter. The country's overall Risk/Reward score was 53.0, just above the regional average of 50.1. Colombia boasts above-average Rewards and Risks, although we caution that the country's intellectual property regime will continue to represent barriers to multinational involvement. Nevertheless, Colombia will continue to be of interest from a longer-term point of view, not least on account of its substantial population.

Key Trends and Developments

In April 2016, Colombia's Health Minister, Alejandro Gaviria, announced that the government will issue a Declaration of Public Interest, which will provide a legal pathway for the compulsory license on Novartis' anticancer drug, Gleevec/ Glivec (imatinib), in Colombia. This is the first step for the Superintendency of Commerce to issue the compulsory license for the production of this drug in Colombia.

In April 2016, Tecnoquimicas, one of the largest domestic drugmakers in Colombia, entered a partnership with mAbxience, a Spanish biopharmaceutical company specialized in research, development and manufacturing of biosimilars. The development is expected to increase the industry's capacity to supply biosimilars.

BMI Economic View

Headline growth in Colombia will continue to decelerate in 2016. Elevated inflation and weakening labour market dynamics will erode households' purchasing power, while rising interest rates will make capital more expensive to obtain, undermining real private consumption growth. We forecast real GDP growth of 2.4% in 2016 (revised from 2.9% previously) and 2.8% in 2017 (from 3.3% previously), notably slower than the average expansion of 4.6% during the previous five years.

BMI Political View

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Brazil Pharmaceuticals & Healthcare Report Q3 2016
- Czech Republic Pharmaceuticals & Healthcare Report Q3 2016
- Bahrain Pharmaceuticals & Healthcare Report Q3 2016
- China Pharmaceuticals & Healthcare Report Q3 2016
- Egypt Pharmaceuticals & Healthcare Report Q3 2016